ImmuPharma PLC (IMM) - Cash Flow Conversion Efficiency

Latest as of June 2025: -2.979x

Based on the latest financial reports, ImmuPharma PLC (IMM) has a cash flow conversion efficiency ratio of -2.979x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.00 Million ≈ $-122.04 USD) by net assets (GBX336.70K ≈ $40.97 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ImmuPharma PLC (IMM) net asset quality to measure how much of total assets are equity-financed.

ImmuPharma PLC - Cash Flow Conversion Efficiency Trend (2004–2024)

This chart illustrates how ImmuPharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IMM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

ImmuPharma PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ImmuPharma PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Virpax Pharmaceuticals Inc NASDAQ:VRPX	3.142x
Jpmorgan Global Core Real Assets Ltd LSE:JARA	0.046x
PCI Biotech Holding ASA OL:PCIB	-0.501x
Arecor Therapeutics PLC LSE:AREC	-0.178x
Baltic Bridge S.A. WAR:WIS	N/A
Oxurion NV BR:OXUR	0.097x
Water Ways Technologies Inc V:WWT	0.002x
VATIC VENTURES CORP. F:V8V	0.002x

Annual Cash Flow Conversion Efficiency for ImmuPharma PLC (2004–2024)

The table below shows the annual cash flow conversion efficiency of ImmuPharma PLC from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see ImmuPharma PLC (IMM) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-542.86K ≈ $-66.05	GBX-1.77 Million ≈ $-215.25	3.259x	+352.29%
2023-12-31	GBX1.06 Million ≈ $128.52	GBX-1.36 Million ≈ $-166.01	-1.292x	-38.87%
2022-12-31	GBX2.52 Million ≈ $307.02	GBX-2.35 Million ≈ $-285.57	-0.930x	+15.06%
2021-12-31	GBX4.41 Million ≈ $536.99	GBX-4.83 Million ≈ $-588.06	-1.095x	-217.56%
2020-12-31	GBX9.65 Million ≈ $1.17K	GBX-3.33 Million ≈ $-405.09	-0.345x	+56.96%
2019-12-31	GBX5.27 Million ≈ $641.11	GBX-4.22 Million ≈ $-513.62	-0.801x	-29.36%
2018-12-31	GBX7.62 Million ≈ $927.50	GBX-4.72 Million ≈ $-574.43	-0.619x	+49.93%
2017-12-31	GBX3.57 Million ≈ $434.91	GBX-4.42 Million ≈ $-537.91	-1.237x	-5.76%
2016-12-31	GBX5.55 Million ≈ $674.79	GBX-6.49 Million ≈ $-789.17	-1.170x	+52.34%
2015-12-31	GBX1.69 Million ≈ $205.67	GBX-4.15 Million ≈ $-504.74	-2.454x	-462.18%
2014-12-31	GBX5.71 Million ≈ $694.18	GBX-2.49 Million ≈ $-303.03	-0.437x	+39.73%
2013-12-31	GBX5.40 Million ≈ $657.48	GBX-3.91 Million ≈ $-476.20	-0.724x	-87.19%
2012-12-31	GBX8.42 Million ≈ $1.02K	GBX-3.26 Million ≈ $-396.30	-0.387x	-43.72%
2011-12-31	GBX12.51 Million ≈ $1.52K	GBX-3.37 Million ≈ $-409.67	-0.269x	+37.19%
2010-12-31	GBX15.97 Million ≈ $1.94K	GBX-6.84 Million ≈ $-832.84	-0.429x	-164.78%
2009-12-31	GBX18.08 Million ≈ $2.20K	GBX11.96 Million ≈ $1.46K	0.662x	+389.02%
2008-12-31	GBX11.24 Million ≈ $1.37K	GBX-2.57 Million ≈ $-313.06	-0.229x	+80.78%
2007-12-31	GBX3.05 Million ≈ $371.10	GBX-3.63 Million ≈ $-441.91	-1.191x	-239.23%
2006-03-31	GBX2.50 Million ≈ $304.66	GBX-879.00K ≈ $-106.95	-0.351x	-1391.04%
2005-03-31	GBX993.00K ≈ $120.82	GBX27.00K ≈ $3.29	0.027x	+2559.21%
2004-03-31	GBX978.00K ≈ $118.99	GBX1.00K ≈ $0.12	0.001x	--

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$272.19K

GBX2.24 Billion GBX

Market Cap Rank

#31120 Global

#994 in UK

Share Price

GBX4.45

Change (1 day)

+11.25%

52-Week Range

GBX1.50 - GBX17.60

All Time High

GBX190.00